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ABSTRACT
Background: Newborn calves are born immunosuppressed, hypogammaglobulinemic, immunologically immature, and 
therefore more vulnerable to many infectious diseases. During pregnancy, the fetal-placental environment is regulated 
by Th2-type cytokines that neutralize Th1 responses, an important factor for immune defense against viral agents. The 
ingestion and absorption of colostral immunoglobulins enhance the immunity of the neonate. However, the presence of 
maternal antibodies might negatively affect the success of parental vaccination in the first two months of life. This study 
aimed to evaluate the effecacy of parenteral vaccination in newborn calves with high titers of maternal antibodies against 
respiratory viruses.
Materials, Methods & Results: Twenty-eight Holstein calves were allocated to the vaccinated group (VAC, n = 18) or an 
unvaccinated control group (NVAC, n = 10). The initial vaccination with 5 mL of a commercial vaccine occurred around 
the 14th day of life (D14) and the booster at D35. Respiratory and diarrhea symptoms were evaluated at D12, D14, D16, 
D20, D31, D36, D45, D53, and D60. Blood samples were taken for leukogram, haptoglobin, and seroneutralization of 
BVDV, BoHV-1, BRSV, and BPI3V, at the time of vaccination at D14 (T1), at booster (D35, T2), and 21 days after the 
booster (D56, T3). Despite the increased prevalence of BRD during the period of the study, no calves from either group 
exhibited respiratory disease at D12 or D14. In subsequent assessments, the frequency of BRD increased over time in the 
VAC group until it reached a maximum prevalence of 38.9% (7/18) at D31. In the NVAC group, the maximum prevalence 
observed was 40% at D45 and D60. A comparison of the frequencies for BRD cases showed a statistical trend at D36 
(P = 0.07), with a higher prevalence for the NVAC group (30%) in relation to the VAC group (5.6%). For the NVAC group, 
a greater number of total leukocytes was observed at T3 (P = 0.038) and granulocytes (trend) at T2 (P = 0.066). Time 
analysis demonstrated a decrease in haptoglobin concentration in both groups (NVAC, P = 0.005 and VAC, P = 0.006), 
with a reduction in the values at T1 and T3 (NVAC = 0.005 and VAC = 0.024). Antibody titers were similar between groups 
for BVDV, BoHV-1, and BRSV. Higher titers for BPI3V were observed for the VAC group at D56 (P = 0.045).
Discussion: The early-onset BRD was present in both groups between 30 and 60 days of age, based on the higher preva-
lence observed. These data reinforce the importance of early immunization programmes before infection. Factors such as 
management practices and facilities may have also contributed to the higher prevalence of BRD. The increased number of 
leukocytes and neutrophils at T2 (D35) and T3 (D56) in the NVAC group points to a stronger inflammatory response to 
various types of potential challenges. The inflammatory leukocyte profile explains the higher haptoglobin values observed 
in the NVAC group at T2 (D35). The similarity of titers of antibodies against BVDV, BoHV-1, and BRSV between groups 
may indicate that vaccinating the calves at 14 days of age did not induce a humoral immune response to these viruses, 
likely due to interference from the maternal antibodies. Early vaccination prevented a drop in specific viral antibodies and 
promoted partial protection for vaccinated calves around 14 days of age, with a decrease in the intensity of the inflamma-
tory response at the peak of the disease and a higher concentration of antibodies against BPI3V after the booster.
Keywords: bronchopneumonia, colostrum, maternal antibodies. 
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INTRODUCTION
Newborn calves are susceptible to antigenic 
challenges after birth as they are born hypogamma-
globulinemic and immunologically immature [9]. During 
pregnancy, the fetal-placental environment is regulated 
by Th2-type cytokines that neutralize Th1 responses, an 
important factor for immune defense against viral agents 
[5]. Temporary protection of newborns against respiratory 
viruses is enhanced by ingestion and absorption of colos-
trum containing immunoglobulins (Igs) responsible for 
the neutralization and elimination of the pathogen before 
it reaches the organs [8,20]. The maximum frequency of 
bovine respiratory disease (BRD) in heifers aged between 
30 and 40 days is an indication of reduction of maternal 
antibodies and need for the establishment of early im-
munization protocols for prevention of BRD [14].
Vaccine-induced immune responses in new-
borns might be suppressed by maternal antibodies in 
the first two months of life [6,22]. Antibodies titers 
against BRD do not increase after early vaccination of 
calves, but this protocol can induce cellular response 
and immunological memory [7,17].
Nowadays, approximately nine parenteral and 
one intranasal vaccines against BRD are registered in 
Brazil [3] and most formulations contain aluminum 
hydroxide as adjuvant, which predominantly induces 
humoral immune response. Studies about effectiveness of 
protocols of vaccination are very scarce. This scenario is 
aggravated when applied to the calf rearing system. The 
aim of this study was to evaluate the effecacy of parenteral 
vaccination in newborn Holstein calves with high titers of 
maternal antibodies against respiratory viruses.
MATERIALS AND METHODS
Sampling
The study was carried out between 2016 and 
2017 and conducted on a high production dairy farm, 
with an average of 70,000 L of milk/day, located in 
the west region of the state of São Paulo (22º 10’S, 
47º 15’W), Brazil.
Vaccination protocol
Colostrum donor cows underwent vaccination 
protocols established in the farm’s health calendar. The 
first vaccination started at 60 days of age, followed 
by booster at 90 days of age and semestral revaccina-
tions, carried out in April and October. The farm used 
the commercial vaccine1 containing inactivated type 
1 (5960) and type 2 (53637) BVDV strains; BoHV-1 
(Cooper) and BPI3V (RLB 103) live/thermosensitive; 
BRSV (375) live/attenuated; Leptospira canicola, L. 
grippotyphosa, L. hardjo, L. icterohaemorrhagiae 
and L. pomona inactivated, associated with Quil A, 
cholesterol and Amphigen as adjuvants. 
Management
Management adopted for the assistance to 
newborn calves was followed according to the farm 
protocol. Calvings were assisted and calves were im-
mediately separated from their mothers. Colostrum 
screening was performed after the first milking with 
the use of a colostrometer and reference value for an 
IgG concentration ≥ 5,000 mg/dL. The first feeding of 
fresh colostrum (3 L) was offered in a bottle between 
birth and the 1st two hours of life, the second feeding 
was offered at 6 h of age, with a volume ranging from 
2 to 3 L, depending on the cow’s production. After 
colostrum, heifers were suckled with 6 L of milk/
day, commercial ration, and water ad libitum until the 
weaning period (≈ 70 days of age).
Experimental design
During the experimental period, calves were 
kept in individual suspended cages (1.2 m2), distributed 
in a covered and ventilated shed with an area of 112.5 
m2 and height of 4.5 m (1.18 unit/m2), used exclusively 
for this work to prevent the contact of the calves in this 
research, considering that the farm used live intranasal 
vaccine containing BRSV, BPI3V, and BoHV-1.
Holstein calves (n = 28) were selected for field 
research, randomly distributed into 2 experimental 
groups: VAC group - animals vaccinated between 11-22 
days of age and revaccinated between 32-43 days (n = 
18); and NVAC group - unvaccinated control animals (n 
= 10). A volume of 5 mL of a commercial vaccine1 was 
applied subcutaneously in the region of the neck. Scores 
for BRD and diarrhea were evaluated at ages of (days) 
D12, D14, D16, D20, D31, D36, D45, D53, and D60.
Blood samples from the calves were obtained 
for leukogram (tubes containing EDTA), haptoglobin 
and seroneutralization (tubes without anticoagulant) at 
the vaccination day (T1-11 at 22 days), booster (T2-32 
at 43 days), and 21 days after the 2nd dose of the vac-
cine (T3-53 at 64 days), by puncture of jugular vein. 
Aliquots were frozen at -80ºC.
Calves were submitted to clinical evaluation be-
fore the application of the 1st dose of the vaccine (D14), 
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21 days after the 1st dose (D35), and 21 days after the 
2nd dose (D56). Respiratory disease was monitored ac-
cording Poulsen & McGuirk [18] and the sum of scores 
≥ 5.0 was considered positive for respiratory disease.
Total and differential count of leukocytes were 
determined in an automatic device2 and serum hapto-
globin (Hp) concentration was assessed according Jones 
and Mould [12]. Titers of specific antibodies for the 
respiratory viruses (BVDV, BoHV-1, BRSV, BPI3V) 
were evaluated by the seroneutralization (SN) technique 
according to the manual established by OIE [16]. 
Specific cellular immune response against 
respiratory viruses was assessed by analyzing the 
proliferation of mononuclear blood cells (MN). Mono-
nuclear blood cells isolation was performed accord-
ing to Novo et al. [15] followed by adjusting the cell 
concentration to 5x106/mL.
Statistical analysis
The program SPSS version 18 was used. Data 
normality was tested with Shapiro-Wilk and the set of 
non-parametric data was submitted to logarithmic, in-
verse, and quadratic root transformation until parameter-
ization. Titers of antibodies against BVDV-1, BoHV-1, 
BRSV, and BPI3V maintained non-parametric distribu-
tion and were therefore compared between groups by 
the Mann-Whitney test, and between times by Fried-
man test associated with the Wilcoxon test. Parametric 
quantitative variables were compared between groups 
and times simultaneously by the 2-way ANOVA and 
post hoc Bonferroni tests. The association between the 
frequencies (%) of BRD and experimental groups was 
determined by the Chi-square test and Fisher’s test.
RESULTS
Considering the prevalence of BRD, only 
calves serum negative for BRD were included in 
both experimental groups (D12-14). The frequency 
increased over time in the VAC group (D16: 9.1%, 
1/11; D20: 6.3%, 1/16) until it reaches the maximum 
prevalence of 38.9% (7/18) at D31. In the following 
moments, the prevalences were: D36 (5.6%, 1/18); D45 
(23.5%, 4/17); D53 (33.3%, 6/18), and D60 (17.6%, 
3/17). In the NVAC group, the maximum prevalence 
observed was 40% at D45 and D60, and in the moments 
D16, D20, D31, D36, and D53 the frequencies were 
respectively: 0% (0/7); 22.2% (2/9); 20.0% (2/10); 
30.0% (3/10), and 30.0% (3/10). The comparison of the 
BRD frequencies between groups revealed a statisti-
cal trend at D36 (P = 0.07), with a higher prevalence 
in the NVAC (30%) in relation to VAC group (5.6%). 
Means and standard deviations of leukogram 
and Hp are shown in Table 1. The absolute number 
(x10³/µL) of total leukocytes was higher in NVAC group 
at T2 (P = 0.089) and T3 (P = 0.038), with a tendency 
to a greater number of granulocytes in T2 (P = 0.066).
Table 1. Mean values and standard deviations of the leukogram and serum haptoglobin of vaccinated (VAC) and non-vaccinated (NVAC) 
Holstein calves against respiratory virus from 11 to 64 days of life.
Parameter Group T1 T2 T3 P
Leukocytes
NVAC 10.3 ± 3.19 7.86 ± 2.6 8.68 ± 2.55 0.195
VAC 8.7 ± 2.93a 6.11 ± 2.45b 6.7 ± 2.02ab 0.005
P - 0.211 0.089 0.038 -
Granulocytes
NVAC 7.06 ± 2.69 4.6 ± 2.47 4.29 ± 2.22 0.051
VAC 5.63 ± 2.24a 3.11 ± 1.37b 3.06 ± 1.22b 0.000
P - 0.166 0.066 0.122 -
Lymphocytes
NVAC 2.21 ± 0.8b 2.4 ± 0.79ab 3.31 ± 0.95a 0.019
VAC 2.20 ± 1.01 2.31 ± 1.28 2.81 ± 1.48 0.310
P - 0.939 0.677 0.234 -
Monocytes
NVAC 1.03 ± 0.34 0.78 ± 0.28 0.93 ± 0.31 0.234
VAC 0.91 ± 0.39 0.76 ± 0.25 0.79 ± 0.19 0.316
P - 0.173 0.765 0.165 -
Hp (mg/dL)
NVAC 2.38 ± 1.87ab 3.2 ± 5.48a 0.98 ± 0.25b 0.005
VAC 1.46 ± 0.23ab 1.54 ± 0.39a 1.4 ± 0.9b 0.006
P - 0.297 0.687 0.176 -
T= times; T1= 11-22 days; T2= 32-43 days; T3= 53-64 days. P (row)= comparison between groups; P (column)= comparison between 
times. Analysis between groups and times was performed using the 2-way ANOVA test. Different lowercase letters on the same line 
indicate differences between the moments by the Bonferroni test. Significance was considered when P ≤ 0.05.
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Analysis of variance over time in each group 
detected significant variations for leukocyte values only 
in the VAC group between T1 and T3 (NVAC = 0.195; 
VAC = 0.005). Multiple comparisons between times 
revealed a decrease in total leukocytes between T1 and 
T2 (P = 0.005), with similar values between T2 and T3 
(P ≥ 0.05). The absolute number of granulocytes was 
also affected by time in the VAC group (P = 0.001), 
with a decrease between T1 and T2 (P = 0.001) and 
between T1 and T3 (P = 0.001). In contrast, the abso-
lute number of lymphocytes was affected by time only 
in the NVAC group (P = 0.019) with an increase in the 
number of cells between T1 and T3 (P = 0.02). The 
absolute values of monocytes did not change over time 
in the NVAC (P = 0.234) and VAC group (P = 0.316).
Haptoglobin showed a similar value between 
groups throughout the study (P ≥ 0.176). Time analy-
sis by two-way ANOVA with post hoc Bonferroni 
demonstrated a decrease in Hp concentration in both 
groups (NVAC, P = 0.005 and VAC, P = 0.006), with a 
reduction in the values obtained in T1 and T3 (NVAC 
= 0.005 and VAC = 0.024).
Antibody titers obtained for the respiratory 
viruses are shown in Table 2. The comparison of the 
antibodies titers between groups showed differences 
only for titers of BPI3V in T3, with higher values in 
the VAC group (P = 0.045). The dynamic over time 
revealed constant values for antibody titers against 
BVDV in the NVAC from T1 to T3 (P = 0.417). On the 
other hand, VAC calves showed variations in the titers 
of antibodies over time (P = 0.011), with a maximum 
value in T2, which differed from the titer in T3 (P = 
0.049). The peak of antibody titer against BVDV at T2 
can be explained by the seroconversion of two calves 
(20%, 2/10) from NVAC and three calves from the 
VAC group (16.66%, 3/18).
Table 2. Neutralizing antibodies, mean values and standard deviations of the proliferation of mononuclear cells stimulated with 
ConA and viral strains involved in BRD in vaccinated (VAC) and unvaccinated (NVAC) Holstein calves against respiratory virus, 


















NVAC 6.31 (3.32-9.3) 7.8 (6.31-8.30) 6.31 (5.31-8.3) 0.417
VAC 7.30 (0.0-9.3)ab 8.3 (6.31-10.2)a 7.3 (5.3-9.3)b 0.011
BoHV-1
NVAC 8.96 (7.97-8.96)a 7.97 (5.97-8.96)a 6.97 (2.98-8.96)b 0.048
VAC 8.96 (3.98-8.96)a 6.97 (2.98-8.96)ab 6.97 (5.9-8.96)b 0.013
BRSV
NVAC 2.98 (0.99-4.0) 2.98 (0.99-2.98) 1.49 (0.00-2.98) 0.096
VAC 2.98 (0.99-5.97 1.99 (0.00-3.98) 1.99 (0.00-3.98) 0.150
BPI3V
NVAC 4.98 (3.98-7.97)a 6.97 (5.97-8.96)b 5.48 (3.98-9.96)ab 0.002

















NVAC 0.58 ± 0.51 0.84 ± 0.66 1.04 ± 0.87 0.607
VAC 0.51 ± 0.25ª 1.23 ± 0.94b 1.8 ± 0.55c 0.000
ConA
NVAC 2.11 ± 0.74 2.43 ± 0.56 1.88 ± 0.37 0.200
VAC 2.22 ± 0.52ab 2.31 ± 0.4a 1.85 ± 0.29b 0.008
BVDV-1
NVAC 1.41 ± 0.7 1.62 ± 0.56 1.64 ± 0.42 0.658
VAC 1.6 ± 0.61ab 2.02 ± 0.66a 1.39 ± 0.57b 0.026
BVDV-2
NVAC 1.24 ± 0.76 1.09 ± 0.94 1.05 ± 0.7 0.607
VAC 1.33 ± 0.58 0.97 ± 0.56 1.02 ± 0.62 0.607
Hobi-like
NVAC 1.64 ± 0.51ª 2.03 ± 0.45ª 1.53 ± 0.33ª 0.077
VAC 1.71 ± 0.61ab 2.09 ± 0.6a 1.53 ± 0.41b 0.026
BoHV-1
NVAC 0.65 ± 0.36 0.97 ± 1.08 0.44 ± 0.24 0.321
VAC 0.85 ± 0.63 0.54 ± 0.53 0.57 ± 0.36 0.276
T= times; P= comparison between times (Friedman test). Different lowercase letters on the same line indicate differences between 
the moments by the Wilcoxon test. Significance was considered when P ≤ 0.05.
Medians of antibody titers against BoHV-1 
decreased between T1 and T3 in NVAC (P = 0.048) 
and VAC groups (P = 0.013). Multiple comparisons 
between times revealed differences between T1 and T3 
(P = 0.027) and T2 and T3 (P = 0.049) in NVAC group. 
In VAC group the differences were detected between 
T1 and T3 (P = 0.032), in addition to seroconversion 
of 2 calves in T2 (11.11%, 2/18) and 3 calves in T3 
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(16.66%, 3/18). For BRSV, a tendency for a decrease 
in antibodies titers was observed over time but only in 
NVAC group (P = 0.096). Therefore, values obtained 
in the VAC group were constant over time (P = 0.150). 
Seroconversion of one calf (10%, 1/10) was detected at 
T2 in NVAC group, and one calf at T2 and one at T3 
(5.55%, 1/18) from VAC group. Titers of antibodies for 
BPI3V varied over time in both experimental groups 
(NVAC = 0.002; VAC = 0.000). Multiple comparisons 
over time revealed differences between T1 and T2 (P 
= 0.007) and a trend between T2 and T3 (P = 0.073) 
in NVAC; and between T1 and T2 (P = 0.002), T1 and 
T3 (P = 0.032), and between T2 and T3 (P = 0.042) 
in the VAC group. Seroconversion was detected in 3 
calves from NVAC (30%, 3/10) at T2 and in 6 calves 
(33%, 6/18) from VAC at T2.
Means and standard deviations of MN cells 
proliferation are shown in Table 2. The spontaneous 
proliferation of unstimulated MN was greater in the 
VAC group at D56 (P = 0.047). The analysis over time 
by Friedman test showed an increase proliferation of 
MN cells throughout the experiment only in the VAC 
group (NVAC, P = 0.607; VAC, P = 0.000). Multiple 
comparisons using the Wilcoxon test detected differ-
ences between D14 and D35, and D14 and D56 (P = 
0.004 and P = 0.001, respectively), and a trend between 
D35 and D56 (P = 0.088).
Cells stimulated with ConA, BVDV-1, BVDV-
2, BVDV-3, and BoHV-1 did not show differences 
between groups throughout the study (P ≥ 0.05). Time 
analysis showed variations in the proliferative re-
sponse of MN cells stimulated with ConA (NVAC, P 
= 0.200 and VAC, P = 0.008), BVDV-1 (NVAC, P = 
0.658 and VAC, P = 0.026), and BVDV-3 (NVAC, P 
= 0.077; VAC, P = 0.026) in the VAC group. Multiple 
comparisons over time revealed differences between 
T2 and T3 for ConA (P = 0.01); BVDV-1 (P = 0.025), 
and BVDV-3 (P = 0.025). 
Regarding BVDV-2 and BoHV-1, it was not 
possible to detect variations over time for NVAC (P 
= 0.607 and P = 0.321) or VAC group (P = 0.607 and 
P = 0.276).
DISCUSSION 
This research evaluated the influence of 
early vaccination against respiratory viruses on the 
prevalence of BRD, leukogram, and specific immune 
response of Holstein heifers.
Due to the high prevalence observed between 
30 and 60 days of life, our findings suggested early 
BRD infections presented in both experimental groups. 
A large survey demonstrated similar results with in-
cidence of BRD around 22% (630/2874) in the first 3 
months of life of the calves, with most animals being 
treated around 30 days of age [23].
According to the Dairy Calf and Heifer As-
sociation, the occurrence of BRD should be less than 
10% in the pre-weaning period (1 to 60 days of life), 
but we can see a large gap between the goal and the 
reality. These data together reinforce the importance 
of efficient protocols for early immunization before 
the maximum peak of the disease, especially in colder 
months of the year in the southern and southeastern 
regions of Brazil, where the temperatures are below 
the interval between 15 and 25°C characterized as a 
thermoneutral zone of the calves [19].
Far beyond the vaccination protocols, man-
agement practices and facilities are also factors that 
influenced the high prevalence of BRD reported in this 
research, since these factors are practically uncontrol-
lable in a study carried out in the field. The present 
research was carried out in a commercial farm with 
intensive calf rearing in individual suspended housing. 
The intensification of calf production in a small area 
with low ceilings has a negative effect on ventilation, 
insolation of the area, and air quality. In addition, the 
change of beds was carried out only once a week in our 
study. The management practices such as living with 
older calves (odds ratio = 3.21), the presence of a damp 
bed, and the use of maternity for activities other than 
parturition (odds ratio = 2.61) were responsible for the 
increasing prevalence of BRD in calves grouped and 
fed with automatic feeders [13]. 
The present study did not demonstrate the ef-
fect of early parenteral vaccination on the prevalence 
of BRD. In one field survey, vaccination of calves 
between 2 and 5 weeks of life was not associated with 
decreased incidence or mortality from BRD, or with 
growth rates up to 3 months of age [24].
Despite the clear absence of differences be-
tween the prevalence of BRD in both groups, it was 
possible to observe a greater number of leukocytes and 
neutrophils in T2 (D35) and T3 (D56) in the NVAC 
group, pointing to greater intensity of the inflam-
matory response in these animals in the face of the 
multiple natural challenges. This fact also reflected in 
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the leukocyte profile over time, observing the classic 
decrease with age in the number of total leukocytes 
and neutrophils only in the VAC group [4]. The inflam-
matory leukocyte profile also explains the higher Hp 
values observed in the NVAC group at T2, despite the 
absence of statistical differences between the groups.
There are no national data about the efficacy of 
parenteral vaccines in the humoral and cellular immune 
response in calves in the neonatal phase, despite the 
high occurrence of BRD between 30 and 60 days of 
life. Among the commercial injectable vaccines avail-
able in Brazil, we chose a formulation that stimulates 
the best humoral immune response against BVDV 
and BoHV-1 in animals with 8 and 12 months of age 
[1]. The selected vaccine contained an ISCOM (Im-
munestimulating Complexes) and their adjuvants form 
nanoparticles similar to spherical capsules composed 
of cholesterol, amphigen, and saponin derivatives (Quil 
A). The ISCOM is a potent adjuvant which induces 
more generalized immune response, including delayed 
hypersensitivity response, increased serum IgG1 and 
IgG2a, increased IgA secretion in the intestinal mu-
cosa, and production of Th1 and Th2 adaptive response 
dependent on cytokines [2].
The titers of antibodies against BVDV, BoHV-
1, and BRSV were similar between the groups, al-
though the VAC calves showed higher medians of the 
antibodies for all respiratory viruses after the booster 
(D56). The absence of differences between groups 
may indicate that vaccination of calves at 14 days of 
age did not induce humoral immune response to these 
viruses. The interference of maternal antibodies in 
the humoral immune response induced by vaccination 
has been presented in several publications over time 
[6,8,25]. Antibodies titers decreased over time, due to 
the half-life of approximately 23, 21, 36, and 30 days 
for the specific maternal antibodies found for BVDV, 
BoHV-1, BRSV, and BPI3V, respectively [8].
The prevalence observed for BRD between 
D30 and D60 in both groups indicates natural exposure 
to respiratory agents and can be justified by the high 
degree of dissemination of virus by air and the circula-
tion of employees between different areas of the farm. 
Natural infections were suggested in the NVAC group 
by the presence of BVDV, BRSV, and BPI3V antibod-
ies in D35, probably due to the association between 
exposure and vaccine response. Despite the absence of 
differences between specific titers of antibodies in both 
groups, it could be noted that the VAC group showed 
greater oscillations in time for the titers of antibodies 
against BVDV-1 and BPI3-V with a peak at D35. 
The primary vaccination probably generated 
some cellular memory and humoral immune response 
of greater intensity in the presence of natural challenges 
to respiratory pathogens. This may explain the lower 
intensity of inflammatory response in the VAC group 
after the booster. Other factors in addition to the inter-
ference of maternal antibodies must be considered in 
the response to early vaccination. In relation to BVDV, 
it is known that inactive vaccines induce an immune 
response of low intensity and duration [12]. Therefore, 
comparison of Brazilian researches and international 
data with modified live vaccines is limited.
Regarding to BoHV-1, there was a mild humor-
al immune response after vaccinations with a formula-
tion containing the modified live and thermosensitive 
virus, considering the slight decrease in antibodies 
over time only in the VAC group. It was demonstrated 
the interference of maternal antibodies on the vaccine 
response induced by live-modified BoHV-1 [8]. Con-
sidering BRSV, low titers of antibodies were observed 
in both groups, but the VAC group showed stability 
in titers concentrations between D14 to D56. These 
absence of differences can be interpreted as ineffec-
tiveness of the vaccine; however previous research has 
demonstrated protection against acute clinical disease 
caused by BRSV in the absence of seroconversion 
after vaccination in calves with high titers of maternal 
antibodies [21]. Potentially calves with circulating 
maternal antibodies can develop virus-specific T cell 
responses [6]. BRSV has the particularity of inducing 
short-term immune memory [10].
Cellular immune response evaluated by the 
proliferation of MN cells stimulated with BVDV-1, 
BVDV-2, BVDV-3 (Hobi-like), and BoHV-1 strains 
was similar between the groups. Woolums et al. [25] 
also found no differences in the intensity of the cellular 
immune response in beef calves vaccinated with a dose 
of injectable or intranasal vaccine at 14 days of age 
compared to the NVAC group. In the abovementioned 
research, MN were stimulated with BoHV-1, BVDV, 
BRSV, and Pasteurella multocida. The cellular immune 
response was evaluated by the detection of CD25+ cells, 
production of IFN-gamma, and proliferative response. 
At the time of this study, Brazil did not have yet an 
intranasal vaccine against BRD as recently. The use 
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of this vaccine in the first week of life and around 
weaning is already a reality on dairy farms, although 
further studies similar to Woolums et al. [25] for the 
use in the field are needed. 
Endsley et al. [7] analyzed three experimental 
groups: G1- calves primovaccinated with 7 weeks of 
age with BVDV-1 and BVDV-2 live and modified; 
G2- calves primovaccinated with 7 weeks of age with 
inactivated BVDV-1 and BVDV-2; G3- non-vaccinated 
control calves. There was no vaccination booster after 
the first dose in both groups of vaccinated calves. The 
authors also did not observe evidence of the induction 
of the humoral immune response after vaccination, 
however they found a higher proportion of lymphocytes 
expressing the CD25 marker in G1, after culturing the 
mononuclear cells stimulated with the BVDV-1 and 
BVDV-2 strains. The authors did not prove cellular 
immune response in the G2 and G3, which is consistent 
with the findings of this research, even considering the 
younger animals included by our team.
Commercial vaccines with live modified 
BVDV were not a reality in Brazil during the time that 
this research was carried out. There is currently a mon-
ovalent vaccine on the market and some formulations 
are being registered. The use of live modified vaccines 
can be a tool to induce cellular immune response in 
young calves, but it must be validated for Brazilian 
conditions [7]. 
We cannot fail to report that in this study, the 
proliferation of non-challenged cells was greater in the 
VAC group, in addition to the greater intensity of pro-
liferative response when MN cells were stimulated with 
BVDV-1 and Hobi-like around the peak of BRD. This 
fact may suggest the production of cellular memory 
after the first vaccination of the calves, when cells 
with a Th2 profile mainly produce IL-4, IL-5, and IL-6 
cytokines. The IL-4 is able to induce the activation of 
B lymphocytes, which undergo clonal expansion and 
differentiate into memory cells or mature plasma cells 
[5]. The fact that the VAC group had previous contact 
with the antigens corroborates to the greater intensity 
of cell proliferation.
In general, this research showed evidence 
that the early vaccination of calves contributed to the 
lower occurrence of respiratory disease under natural 
challenges provided by an environment full of risk 
factors in the field. The subtle differences observed 
between the experimental groups demonstrated lower 
intensity of the inflammatory process in the phase of 
greater occurrence of BRD, higher titers of antibod-
ies against BPI3V after booster, lower frequency of 
seroconversion against BoHV-1, and stability in the 
titers of antibodies against BRSV presented in calves 
vaccinated at 14 days of age.
CONCLUSIONS
Despite the partial efficacy of the parenteral 
vaccination against the respiratory viruses observed 
in calves vaccinated around 14 days of age, it can be 
concluded that the decrease in the intensity of the in-
flammation and the higher antibodies against BPI3V 
estimulated cellular memory and humoral immune 
response to greater intensity when compared to unvac-
cinated calves. Such factors may contribute positively 
to heifers to face the natural exposure to the respiratory 
viruses and the additional environmental and manage-
ment risk factors presented in the dairy farms.
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